Shares of IQVIA Holdings Inc. (IQV) soared 13.49% during Tuesday's regular trading session, as the contract research organization reported second-quarter financial results that handily exceeded Wall Street expectations and raised its full-year 2026 outlook.

The company posted adjusted earnings of $3.15 per share, a 12.1% increase from $2.81 a year ago and well above the $3.03 consensus estimate. Revenue climbed 8.7% to $4.37 billion, beating the $4.30 billion analysts had forecast. IQVIA also lifted its full-year guidance, now projecting adjusted EPS of $12.80 to $13.00, up from the prior $12.65 to $12.95, and revenue of $17.28 billion to $17.48 billion, compared with the previous $17.15 billion to $17.35 billion range.

The strong performance was fueled by robust demand for clinical research and healthcare data services. Research & Development Solutions net new bookings surged 19% year-over-year to $3.15 billion, producing a book-to-bill ratio of 1.22x, while the contracted backlog reached $34.2 billion. CEO Ari Bousbib cited favorable indicators across segments pointing to sustained momentum, and analysts noted that recovering biotech funding and increased outsourcing by drugmakers continue to support the company's growth trajectory.